OBJECTIVE: The aim of this work was to verify the tolerability and the preliminary clinical results of intensive intravesical instillations of a mitomycin C (MMC) regimen. PATIENTS AND METHODS: From September 2007 to November 2009, 40 consecutive evaluable patients with pathologically confirmed intermediate-risk non-muscle-invasive bladder cancer (NMIBC) were enrolled after complete transurethral resection of all visible tumors. The mean age of the patients was 64.5 years. 40 mg MMC diluted in 50 ml of saline was instilled in the bladder three times a week for 2 weeks. The median follow-up was 9 months. RESULTS: All patients fulfilled the scheduled treatment. The local adverse events seen were negligible, while no significant deviation from normal values was observed in blood counts for each patient. Twenty-three of 40 patients (57.5%) showed negative at the cystoscopic control which was performed every 3 months with normal spontaneous and washing cytological exams. CONCLUSION: MMC is a well-known chemotherapeutic agent for the intravesical therapy of NMIBC. With a view to improving its results, we changed the frequency and intensity of the instillations. No significant local or systemic toxicity was reported. Intensive intravesical instillations of MMC might become a tool in the management of NMIBC.

Racioppi, M., Volpe, A., Cappa, E., D'agostino, D., Pinto, F., D'addessi, A., Sacco, E., Bassi, P., Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach., <<UROLOGIA INTERNATIONALIS>>, 2010; 85 (3): 266-269 [http://hdl.handle.net/10807/94123]

Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach.

Racioppi, Marco;Volpe, Andrea;Cappa, Emanuele;D'Agostino, Daniele;Pinto, Francesco;D'Addessi, Alessandro;Sacco, Emilio;Bassi, Pierfrancesco
2010

Abstract

OBJECTIVE: The aim of this work was to verify the tolerability and the preliminary clinical results of intensive intravesical instillations of a mitomycin C (MMC) regimen. PATIENTS AND METHODS: From September 2007 to November 2009, 40 consecutive evaluable patients with pathologically confirmed intermediate-risk non-muscle-invasive bladder cancer (NMIBC) were enrolled after complete transurethral resection of all visible tumors. The mean age of the patients was 64.5 years. 40 mg MMC diluted in 50 ml of saline was instilled in the bladder three times a week for 2 weeks. The median follow-up was 9 months. RESULTS: All patients fulfilled the scheduled treatment. The local adverse events seen were negligible, while no significant deviation from normal values was observed in blood counts for each patient. Twenty-three of 40 patients (57.5%) showed negative at the cystoscopic control which was performed every 3 months with normal spontaneous and washing cytological exams. CONCLUSION: MMC is a well-known chemotherapeutic agent for the intravesical therapy of NMIBC. With a view to improving its results, we changed the frequency and intensity of the instillations. No significant local or systemic toxicity was reported. Intensive intravesical instillations of MMC might become a tool in the management of NMIBC.
Inglese
Racioppi, M., Volpe, A., Cappa, E., D'agostino, D., Pinto, F., D'addessi, A., Sacco, E., Bassi, P., Intensive intravesical mitomycin C therapy in non-muscle-invasive bladder cancer: a dose intensity approach., <<UROLOGIA INTERNATIONALIS>>, 2010; 85 (3): 266-269 [http://hdl.handle.net/10807/94123]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/94123
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact